Some evidence indicates that alterations in some driver genes (TP53, KRAS, EGFR, SMAD4) in advanced NSCLC may impact the immune microenvironment and response to ICIs (7, 8). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.